EZM0414 (IPN60210)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for EZM0414 (IPN60210), covering 2025-05-11 to 2025-05-11. Get the full timeline:
Most recent: Clinical Trial Update: A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma [Phase 1]